Literature DB >> 12445956

Polytherapy in epilepsy: the experimental evidence.

Stanisław J Czuczwar1, Kinga K Borowicz.   

Abstract

Monotherapy is recommended preferentially among newly diagnosed epileptic patients. In monotherapy-resistant patients polytherapy may be necessary. Two antiepileptic drugs may produce antagonistic, additive, and supra-additive (synergistic) anticonvulsant effects. The drug combination providing the supra-additive effect seems of clinical significance. However, when the supra-additive anticonvulsant efficacy is also associated by a distinct increase in toxicity, the protective index may be not affected or even lowered. Synergistic interactions have been shown for the combinations of valproate-phenytoin/ethosuximide, topiramate-carbamazepine/phenobarbital and felbamate-all major conventional antiepileptics. In contrast, the protective action of conventional antiepileptics has not been affected by felbamate at subprotective doses against maximal electroshock in mice. This is indicative that synergism is evident at only some drug ratios. Potential antiepileptic drugs, excitatory amino acid antagonists and calcium channel inhibitors, generally enhanced the protection offered by antiepileptic drugs. The experimental data may be helpful for predicting which drug combinations may prove effective in epileptic patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12445956     DOI: 10.1016/s0920-1211(02)00181-x

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  13 in total

Review 1.  New drugs for the treatment of epilepsy: a practical approach.

Authors:  S Beyenburg; J Bauer; M Reuber
Journal:  Postgrad Med J       Date:  2004-10       Impact factor: 2.401

Review 2.  Neuroprotection as a Potential Therapeutic Perspective in Neurodegenerative Diseases: Focus on Antiepileptic Drugs.

Authors:  D Caccamo; L R Pisani; P Mazzocchetti; R Ientile; P Calabresi; F Pisani; C Costa
Journal:  Neurochem Res       Date:  2015-12-31       Impact factor: 3.996

Review 3.  Combination therapy in epilepsy: when and what to use.

Authors:  Patrick Kwan; Martin J Brodie
Journal:  Drugs       Date:  2006       Impact factor: 9.546

4.  Synergistic anticonvulsant effects of pregabalin and amlodipine on acute seizure model of epilepsy in mice.

Authors:  Itefaq Hussain Qureshi; Azra Riaz; Rafeeq Alam Khan; Afaq Ahmed Siddiqui
Journal:  Metab Brain Dis       Date:  2017-03-09       Impact factor: 3.584

5.  Increased Antiseizure Effectiveness with Tiagabine Combined with Sodium Channel Antagonists in Mice Exposed to Hyperbaric Oxygen.

Authors:  Ivan T Demchenko; Sergei Yu Zhilyaev; Olga S Alekseeva; Alexander I Krivchenko; Claude A Piantadosi; Heath G Gasier
Journal:  Neurotox Res       Date:  2019-05-30       Impact factor: 3.911

6.  Isobolographic analysis of interactions between loreclezole and conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model.

Authors:  Jarogniew J Luszczki; Neville Ratnaraj; Philip N Patsalos; Stanislaw J Czuczwar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-04-08       Impact factor: 3.000

7.  Evaluation of interactions between cannabinoid compounds and diazepam in electroshock-induced seizure model in mice.

Authors:  Nima Naderi; Farzad Aziz Ahari; Bijan Shafaghi; Azadeh Hosseini Najarkolaei; Fereshteh Motamedi
Journal:  J Neural Transm (Vienna)       Date:  2008-06-25       Impact factor: 3.575

8.  Interactions between tiagabine and conventional antiepileptic drugs in the rat model of complex partial seizures.

Authors:  K K Borowicz; M Zadrozniak; J J Luszczki; S J Czuczwar
Journal:  J Neural Transm (Vienna)       Date:  2008-01-11       Impact factor: 3.575

9.  Isobolographic profile of interactions between tiagabine and gabapentin: a preclinical study.

Authors:  Jarogniew J Luszczki; Stanislaw J Czuczwar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-02-19       Impact factor: 3.000

10.  Truly "rational" polytherapy: maximizing efficacy and minimizing drug interactions, drug load, and adverse effects.

Authors:  Erik K St Louis
Journal:  Curr Neuropharmacol       Date:  2009-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.